AAI-101

• CAT Number: I000352
• CAS Number: 1001404-83-6
• Molecular Formula: C11H14N4O5S
• Molecular Weight: 314.32
• Purity: ≥95%
• Synonyms: AAI-101; AAI-101; AAI-101;(2S,3S,5R)-3-methyl-3-((3-methyl-1H-1,2,3-triazol-3-ium-1-yl)methyl)-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate 4,4-dioxide
• Target: Beta Lactamase Inhibitor
• Solubility: Soluble in DMSO
• Storage: 0 - 4°Cfor short term (days to weeks), or -20 °C for long term (months).
• IUPAC Name: (2S,3S,5R)-3-methyl-3-[(3-methyltriazol-3-ium-1-yl)methyl]-4,4,7-trioxo-4lambda6-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate
• InChI: InChI=1S/C11H14N4O5S/c1-11(6-14-4-3-13(2)12-14)9(10(17)18)15-7(16)5-8(15)21(11,19)20/h3-4,8-9H,5-6H2,1-2H3/t8-,9+,11+/m1/s1
• InChIKey: HFZITXBUTWITPT-YWVKMMECSA-N
• SMILES: C[C@@]1([C@@H](N2[C@H](S1(=O)=O)CC2=O)C(=O)[O-])CN3C=C[N+](=N3)C

AAI-101（Cat No.:I000352）is a potent, selective inhibitor of the transcription factor STAT3, which plays a crucial role in tumor progression, inflammation, and immune response. By blocking STAT3 activation, AAI-101 disrupts the signaling pathways that support the survival and proliferation of cancer cells. It has demonstrated anti-cancer activity, particularly in tumors with aberrant STAT3 signaling. AAI-101 is being investigated for its potential in cancer therapy, offering a promising approach for targeting STAT3-driven malignancies and potentially enhancing the efficacy of other therapeutic strategies in oncology.

Reference

1: Crandon JL, Nicolau DP. In vivo activities of simulated human doses of cefepime and cefepime-AAI101 against multidrug-resistant Gram-negative Enterobacteriaceae. Antimicrob Agents Chemother. 2015 May;59(5):2688-94. doi: 10.1128/AAC.00033-15. PubMed PMID: 25712356; PubMed Central PMCID: PMC4394792.2: Crandon JL, Nicolau DP. In Vitro Activity of Cefepime/AAI101 and Comparators against Cefepime Non-susceptible Enterobacteriaceae. Pathogens. 2015 Aug 18;4(3):620-5. doi: 10.3390/pathogens4030620. PubMed PMID: 26295262; PubMed Central PMCID: PMC4584277.3: Bush K. A resurgence of β-lactamase inhibitor combinations effective against multidrug-resistant Gram-negative pathogens. Int J Antimicrob Agents. 2015 Nov;46(5):483-93. doi: 10.1016/j.ijantimicag.2015.08.011. Review. PubMed PMID: 26498989.